A study on the Risk factors for Gallbladder diseases in El-khoms Teaching Hospital, Libya

Ahmed Gomati1, Saleh Elafi1 & Hamad Rafe2
1. Surgery Department, Faculty of Medicine, El-margeb University, El-khoms, Libya.
2. Surgery Department, Faculty of Medicine, Omar Mukhtar University, Derna, Libya.

Abstract: Gallbladder disease (GBD) is one of the most common causes of hospital admission in the developed countries, resulting in a substantial cost to health system. The aim of this study is on demographic, characteristic of GBD patients and the associated risk factors. This case-control study includes 200 patients (cases) with GBD, randomly selected from surgery department at el-khoms teaching hospital, Libya from 1 October 2007 to 30 May 2008. In addition, 200 subjects matched with age & sex from other inpatients not suffering from GBD were chosen as controls. Ethical considerations were taken. A detailed history, physical examination, biochemical measurements and abdominal sonography were done. A well formed questionnaire for each subject was filled and full investigations were done. Of all studied subjects (400), males were 240 (60%) and females were 160 (40%) with a mean age of 49.1 years (ranging from 18 to 70 yrs). The rate of GBD among inpatient cases during the study period were 26% with more predominance among females (fm ratio 5.6:1). Risk factors for GBDs were: positive family history (OR = 1.9, P ≤ 0.05), multipara (OR = 2.9, P < 0.05), use of oral contraceptive pills (OR = 2.98, P < 0.046), hormone therapy (OR = 1.3, P < 0.01), high BMI (OR = 1.3, P < 0.05) and hyperlipidemia (OR = 6.3, P < 0.01). The rate of GBD was high. This was partly explained by unfavorable body mass index, lipid levels, higher prevalence of diabetes, and a more frequent use of oral contraceptives and hormone therapy in subjects.

Key words: Gallbladder diseases, Risk factors, Prevalence, El-khoms Teaching Hospital

I. Introduction

Gallbladder disease is one of the most common causes of hospital admission in middle-aged patients in developed countries (Kang et al., 2003 and Kratzer et al., 1999) resulting in a substantial cost to health systems (Aerts and Penninckx, 2003).

Various numbers of factors including high age, female sex, over-weight, food pattern, and a sedentary lifestyle have been identified to be associated with a higher risk of gallstones (Volzke et al., 2005 and Shaffer, 2006).

Women are 1.5-3 times more frequently affected by gallstones than men. Pregnancies might be the main factor, but also the use of oral contraceptives (OCs) or menopausal hormone therapy (MHT) might play a role (Uhler et al., 2000; Thijs and Knipschild, 1993 and Dhiman and Chawla, 2006). In 31% of pregnant women occurs biliary sludge (Maringhini et al., 1993), which is a potential mediator of gallstone formation. Moreover, use of OC and MHT causes an increase of cholesterol secretion, which promotes gallstone formation via cholesterol super saturation of bile (Mandez-Sanchez et al., 2007).

Supersaturated bile and increased hepatic secretion of cholesterol also possibly link to obesity and gallstones. A further determinant of gallstone formation is diet. A high intake of saturated fat and carbohydrate as well as a high glycemic load and index is associated with an increased gallstones rate, whereas a high fat protects against gall stone disease (Katsika et al., 2005).

Aim of study

This study intends to assess the risk factors associated with occurrence of gallbladder disease.

II. Subjects and Methods

This case-control study included 200 patients (cases) with GBD, randomly selected from surgery department at El-khoms teaching hospital, Libya from 1st October, 2007 to 30th May, 2008. In addition, 200 subjects matched with age and sex, from other inpatients not suffering from GBD was chosen as controls. Ethical considerations were taken. A detailed history, physical examination, biochemical measurements, and abdominal sonography were done. A well-formed questionnaire for each subject was filled and full investigation was done.

Patients were identified as having a hospital admission for gallbladder disease if they had a hospital record where the primary diagnosis was cholelithiasis or cholecystitis (ICD-10 codes K80 –K81) or where any procedure code indicated a cholecystectomy (OPCS 4 codes J18).
A study on the Risk factors for Gallbladder diseases in El-khoms Teaching Hospital, Libya

Body mass index (BMI) was calculated as kg/m² and categorized according to the WHO criteria (underweight: >18.5 kg/m², normal: 18.5-24.9 kg/m², overweight: 25-29.9 kg/m², obese: >30 kg/m²) (WHO, 2000). BMI was calculated using self-reported height and weight collected from the participants were categorized according to the following BMI categories: <18.5, 18.5-24.9, 25-29.9, 30-39.9 and 40+ kg/m².

Serum total cholesterol and HDL and LDL cholesterol levels were measured by enzymatic method (Hitachi 704, Roche, Mannheim, Germany).

Statistical analyses
Continuous data are expressed as means (SD). Nominal data are expressed as percentages. For bivariate analyses, the kruskal-wallis test (continuous data) or t–test (nominal data) was used.

III. Results
Table 1 shows that of all studied subjects (400), males were 240 (60%) and females were 160 (40%) with a mean age of 49.1 years (ranging from 18 to 70 yrs). There was more predominance among females (f:m ratio 5.6:1).

Table 2 shows that risk factors for GBDs were: positive family history (OR=1.9, P<0.05), multipara (OR= 2.9, P<0.05), use of oral contraceptive pills (OR=2.98, P<0.046] , hormone therapy (OR=1.3, P<0.01), and hyperlipidemia (OR=6.3, P<0.01).

Table 3 shows the distribution of studied subject according to body mass index (BMI).

IV. Discussion
The factors adjusted for are well-accepted risk factors for gallstones. Fatness is a well-documented risk factor, especially in women, where the risk of gallstones increases linearly with rising body weight. Diabetes is also associated with gallstones. However, the association might be confounded by factors such as age and BMI (Jorgensen, 1989 and Maclure et al., 1989).

Gallbladder Diseases with BMI and Hyperlipidemia:
Risk factors for GBDs were high BMI (OR= 1.3, P<0.05) and hyperlipidemia (OR=6.3, P<0.01).

The role of serum lipids in the etiology of gallstones is not clearly understood. In general, it is assumed that hyperlipidemia is associated with gallstones. However, several studies found inverse associations of serum HDL, LDL, and total cholesterol with gallstones. Furthermore, a higher prevalence of gallstones among men on cholesterol-lowering diet was observed (Thijs et al., 1990 and Martinez et al., 1997).

Gallbladder Diseases with Multipara and Oral Contraceptive:
Risk factors for GBDs were multipara (OR=2.9, P<0.05) and the use of Oral contraceptive pills (OR=2.98, P<0.046).

Whereas pregnancy is a well-established risk factor for gallstones, the effect of Oral Contraceptive (OC) and menopausal hormonal therapy (MHT) is still controversially discussed. Older studies found a higher risk of gallstones in women who had taken OC. However, the findings in other studies are inconsistent. The progressive reduction in hormone content and the incomparable doses and types of estrogen or progestin in used OC might be possible explanations for this lack of consistency. The underlying hypothesis assumes that the use of OR cause an increase of biliary cholesterol saturation (Kono et al., 1995; Cuevas et al., 2004 and Tsai et al., 2004). Moreover, family history of gallstones is a strong risk factor for gallstone disease. The evidence for a genetic component to gallstone disease has been grown during the last years (Tsai et al., 2005 and Buch et al., 2007).

Gallbladder Diseases with Positive family history:
Risk factors for GBDs was a positive family history (OR=1.9, P<0.05).

Gallstone formation is thought to rely on 3 factors: super saturation of biliary cholesterol due to hepatic hyper-secretion, nucleation of cholesterol monohydrate crystals, and gallbladder hypo motility. The liver has estrogen receptors, and the presence of endogenous estrogens causes cholesterol saturation in the bile, inhibition of chenodeoxycholic acid secretion, and increased cholic acid content. Progestin inhibits gallbladder contraction, encourage bile stasis and has been shown to decrease the gallbladder’s response to cholecystokinin. One study found that exogenous estrogens, given either transdermally or orally, affected physiologic markers in a pattern that favored gallstone formation (Donovan, 1999 and George and Schluger 2000).

Gallbladder Diseases with Hormone therapy
Risk factors for GBDS was hormone therapy (OR=1.3, P<0.01).

Observational evidence suggests that estrogen therapy, including the use of OC and postmenopausal estrogen therapy, is an important risk factor for gallbladder disease. Observational studies indicate up to a 2.5 fold
increased risk of biliary tract conditions related to estrogen therapy. A previous randomized trial examining biliary tract outcomes after estrogen therapy in postmenopausal women was the Heart and Estrogen/Progestin replacement study (HERS), which included women with known cardiovascular disease. HERS data revealed a 38% increased risk for biliary tract surgery in the estrogen therapy group. Thus, limited clinical trial evidence is available to provide unbiased estimates of the true effects and risks of estrogen therapy in postmenopausal women (Nelson et al., 2002 and Boland et al., 2002).

Estrogens appear to influence several key steps in gallstone formation. One study of postmenopausal women found that exogenous CEEs given orally or estradiol given transdermally, decreased nucleation time in vitro, increased cholesterol saturation index and increased biliary arachidonate and prostaglandin E₂ levels. The pattern of findings resulted in both an increased propensity to form cholesterol crystals and an excess saturation of biliary cholesterol, which along with hypo motility of the gallbladder are thought to be key requirements for gallstone formation. The effect of estrogen therapy has also been studied in men who received exogenous estrogens. In an autopsy study of men randomized to estrogen therapy for the treatment of prostate cancer, the rate of Cholecystectomy was higher but the prevalence of Cholelithiasis among estrogen users were lower at time of death (Liu et al., 2008 and Williams et al., 2008).

V. Conclusion
The rate of GBD in this study was high. This was partly explained by unfavorable body mass index, lipid levels, higher prevalence of diabetes and a more frequent use of oral contraceptives and hormone therapy in subjects.

References


Table 1: Age and sex distribution of studied subject:

<table>
<thead>
<tr>
<th>Age Groups</th>
<th>Male</th>
<th>%</th>
<th>Female</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-</td>
<td>0</td>
<td>0</td>
<td></td>
<td>4</td>
</tr>
<tr>
<td>20-</td>
<td>2</td>
<td>6.7</td>
<td>38</td>
<td>22.4</td>
</tr>
<tr>
<td>30-</td>
<td>2</td>
<td>6.7</td>
<td>50</td>
<td>29.4</td>
</tr>
<tr>
<td>40-</td>
<td>0</td>
<td>0</td>
<td>26</td>
<td>15.3</td>
</tr>
<tr>
<td>50-</td>
<td>14</td>
<td>46.6</td>
<td>30</td>
<td>17.6</td>
</tr>
<tr>
<td>60+</td>
<td>12</td>
<td>40</td>
<td>22</td>
<td>12.9</td>
</tr>
<tr>
<td>Total</td>
<td>30</td>
<td>100</td>
<td>170</td>
<td>100</td>
</tr>
</tbody>
</table>

Table 2: Risk factors in studied subject:

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Patient</th>
<th>Controls</th>
<th>O.R.</th>
<th>P- value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes mellitus</td>
<td>20</td>
<td>40</td>
<td>0.44</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Hypertension</td>
<td>18</td>
<td>50</td>
<td>0.26</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Hemolytic anemia</td>
<td>2</td>
<td>2</td>
<td>2.02</td>
<td>0.03</td>
</tr>
<tr>
<td>Ischemic heart</td>
<td>80</td>
<td>52</td>
<td>1.89</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Positive family history</td>
<td>136</td>
<td>84</td>
<td>2.93</td>
<td>&lt;0.045</td>
</tr>
<tr>
<td>Multipara</td>
<td>32</td>
<td>12</td>
<td>2.98</td>
<td>&lt;0.046</td>
</tr>
<tr>
<td>Contraceptive pills</td>
<td>14</td>
<td>4</td>
<td>1.3</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Hormonal therapy</td>
<td>12</td>
<td>2</td>
<td>6.31</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>High cholesterol</td>
<td>24</td>
<td>24</td>
<td>1.0</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Table 3: Distribution of studied subject according to body mass index:

<table>
<thead>
<tr>
<th>BMI</th>
<th>Patient</th>
<th>Controls</th>
<th>O.R</th>
<th>P- value</th>
</tr>
</thead>
<tbody>
<tr>
<td>19-</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>20-</td>
<td>42</td>
<td>52</td>
<td>0.756</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>25-</td>
<td>68</td>
<td>64</td>
<td>1.080</td>
<td></td>
</tr>
<tr>
<td>30-</td>
<td>52</td>
<td>42</td>
<td>1.320</td>
<td></td>
</tr>
<tr>
<td>35-</td>
<td>14</td>
<td>26</td>
<td>0.910</td>
<td></td>
</tr>
<tr>
<td>40+</td>
<td>12</td>
<td>14</td>
<td>0.840</td>
<td></td>
</tr>
</tbody>
</table>